Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: A meta-analysis and systematic review

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 2, 2010, Pages 167-179

  Hart, Jessica E ^a   Jeon, Christie Y ^b   Ivers, Louise C ^c,d,e   Behforouz, Heidi L ^c,d,e   Caldas, Adolfo ^c   Drobac, Peter C ^c,e   Shin, Sonya S ^c,d,e  

^a BROWN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PARTNERS IN HEALTH   (United States)

Author keywords

Directly observed therapy; DOT HAART; HAART; Meta analysis; Review

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION RETRIEVAL; META ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VIRUS INHIBITION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVALS; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953083248     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181d9a330     Document Type: Article

References (116)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. HIV/AIDS Department, World Health Organization, Geneva, Switzerland, 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed November 11, 2008.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
5. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183.
6. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15: 2109-2017.
7. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23: 360-361.
8. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17:10-22.
9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
10. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
11. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(Suppl 1):S2-S10.
12. Ferguson TF, Stewart KE, Funkhouser E, et al. Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care. 2002;14: 607-617.
13. Kumarasamy N, Venkatesh KK, Cecelia AJ, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS. 2008;22:337-344.
14. Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2006;14:27-35.
15. Moreno-Cuerda VJ, Morales-Conejo M, Rubio R. Antiretroviral treatment associated life-threatening adverse events. Med Clin. (Barc) 2006;126:744-749. [in Spanish].
16. Wolf MS, Davis TC, Osborn CY, et al. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2007;65:253-260.
17. Shin S, Munoz M, Espiritu B, et al. Psychosocial impact of poverty on antiretroviral nonadherence among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care (Chic Ill). 2008;7:74-81.
18. Mukherjee JS, Ivers L, Leandre F, et al. Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S123-S126.
19. Krain A, Fitzgerald DW. HIV antiretroviral therapy in resource-limited settings: experiences from Haiti. Curr HIV/AIDS Rep. 2005;2:98-104.
20. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
21. Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S149-S153.
22. Rawlings MK, Thompson MA, Farthing CF, et al. Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/ abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34:174-183.
23. Knobel H, Carmona A, Lopez JL, et al. Adherence to very active antiretroviral treatment: impact of individualized assessment. Enferm Infecc Microbiol Clin. 1999;17:78-81. [in Spanish].
24. Jones DL, Ishii M, LaPerriere A, et al. Influencing medication adherence among women with AIDS. AIDS Care. 2003;15:463-474.
25. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34:191-194.
26. Safren SA, Hendriksen ES, Desousa N, et al. Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care. 2003;15:787-793.
27. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:841-847.
28. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr. 2006; 43(Suppl 1):S127-S133.
29. Koenig LJ, Pals SL, Bush T, et al. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychol. 2008;27:159-169.
30. Ciambrone D, Loewenthal HG, Bazerman LB, et al. Adherence among women with HIV infection in Puerto Rico: the potential use of modified directly observed therapy (MDOT) among pregnant and postpartum women. Women Health. 2006;44:61-77.
31. Nicca D, Moody K, Elzi L, et al. Comprehensive clinical adherence interventions to enable antiretroviral therapy: a case report. J Assoc Nurses AIDS Care. 2007;18:44-53.
32. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18(Suppl 3):S21-S25.
33. Fairley CK, Levy R, Rayner CR, et al. Randomized trial of an adherence programme for clients with HIV. Int J STD AIDS. 2003;14:805-809.
34. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23-S35.
35. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285-297.
36. WHO. Framework for Effective Tuberculosis Control. World Health Organization Global Tuberculosis Programme. Geneva: WHO; 1994.
37. WHO. Treatment of Tuberculosis: Guidelines for National Programmes. 3rd ed. Geneva: World Health Organization; 2003.
38. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. Stop TB Partnership. Geneva: WHO; 2006.
39. Woodward WC. Should directly observed therapy be considered for treatment of HIV? JAMA. 1996;276:1956.
40. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001;110:664-666.
41. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ. 2001;79:1145-1151.
42. Liechty CA, Bangsberg DR. Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS. 2003;17:1383-1387.
43. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38(Suppl 5):S409-S413.
44. Ma M, Brown BR, Coleman M, et al. The feasibility of modified directly observed therapy for HIV-seropositive African American substance users. AIDS Patient Care STDS. 2008;22:139-146.
45. Macalino GE, Mitty JA, Bazerman LB, et al. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clin Infect Dis. 2004;38(Suppl 5):S393-S397.
46. Machouf N, Lalonde RG. Directly observed therapy (DOT): from tuberculosis to HIV. Rev Epidemiol Sante Publique. 2006;54:73-89. [in French].
47. Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to HAART: a pilot program of modified directly observed therapy. AIDS Read. 2001;11:317-319, 324-328.
48. Wohl AR, Garland WH, Squires K, et al. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis. 2004;38(Suppl 5):S388-S392.
49. Pearson CR, Micek M, Simoni JM, et al. Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S134-S141.
50. Maru DS, Kozal MJ, Bruce RD, et al. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:555-563.
51. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep. 2007; 122:472-481.
52. Partners In Health 2008 Annual Report: Keeping Our Promises, Pushing the Boundaries, Ensuring a Sustainable Future. 2008. Available at: http:// www.pih.org/inforesources/annual/PIH2008-annualreport.pdf. Accessed October 10, 2008.
53. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770-778.
54. Arnsten J, Berg K, Li X, et al. Directly Observed Antiretroviral Therapy Provided in Methadone Clinics: A Randomized Controlled Trial. Presented at: 4th International Conference on HIV Treatment Adherence; 2009; Miami, Florida.
55. Babudieri S, Aceti A, D'Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179-180.
56. Foisy MM, Akai PS. Pharmaceutical care for HIV patients on directly observed therapy. Ann Pharmacother. 2004;38:550-556.
57. Goggin K, Gerkovich M, Wright J, et al.Review of a randomized controlled community trial utilizing mDOT. Presented at: 2nd International Conference on HIV Treatment Adherence; March 8-10, 2006; Jersey City, NJ; 2006.
58. Horta A, Mendez J, Gonzalez E, et al. Directly administered antiretroviral therapy (DAART) and methadone for the treatment of HIV-infected patients. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney, Australia. Abstract WEPEB102.
59. Idoko JA, Agbaji O, Agaba P, et al. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS. 2007;18: 760-763.
60. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628-1635.
61. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21:1473-1477.
62. Mitchell CG, Freels S, Creticos CM, et al. Preliminary findings of an intervention integrating modified directly observed therapy and risk reduction counseling. AIDS Care. 2007;19:561-564.
63. Myung P, Pugatch D, Brady MF, et al. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia. Am J Public Health. 2007;97:974-977.
64. Parsons GN, Siberry GK, Parsons JK, et al. Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: A retrospective study. AIDS Patient Care STDS. 2006; 20:275-284.
65. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238-244.
66. Tinoco I, Giron-Gonzalez JA, Gonzalez-Gonzalez MT, et al. Efficacy of directly observed treatment of HIV infection: experience in AIDS welfare homes. Eur J Clin Microbiol Infect Dis. 2004;23:331-335.
67. Tossonian H, Raffa J, Grebely J, et al. The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART. Presented at: XVII International AIDS Conference; 2008; Mexico City, Mexico.
68. Tyndall MW, McNally M, Lai C, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug policy. 2007;18: 281-287.
69. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis. 2006;42:1619-1627.
70. Simoni JM, Amico KR, Pearson CR, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Current Infect Dis Rep. 2008;10:515-521.
71. Ford N, Nachega JB, Engel ME, et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374:2064-2071.
72. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6:e1000100.
73. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012.
74. Malta M, Strathdee SA, Magnanini MM, et al. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction (Abingdon, England). 2008;103:1242-1257.
75. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365:82-93.
76. Altice FL, Springer SA. DAART for human immunodeficiency virus-infected patients: studying subjects not at risk for nonadherence and use of untested interventions. Arch Intern Med. 2010;170:109-110.
77. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9:iii-iv, ix-x, 1-152.
78. Britton A, McKee M, Black N, et al. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4:112-121.
79. Ellington L, Wahab S, Sahami Martin S, et al. Factors that influence Spanish-and English-speaking participants' decision to enroll in cancer randomized clinical trials. Psychooncology. 2006;15:273-284.
80. Peterson ED, Lytle BL, Biswas MS, et al. Willingness to participate in cardiac trials. Am J Geriatr Cardiol. 2004;13:11-15.
81. Gross R, Tierney C, Andrade A, et al. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009;169:1224-1232.
82. Herbison P. Problems with meta-analysis. N Z Med J. 1999;112:38-41.
83. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060.
84. Bangsberg D, Hammer G, Reynolds M, et al. Adherence Case Management (ACM) Does Not Sustain the Effect of Modified Directly Observed Therapy (MDOT) in HIV-Positive Homeless and Marginally Housed (H/M) Individuals (or does it?). Presented at: 4th International Conference on HIV Treatment Adherence; 2009; Miami, FL.
85. Maru DS, Bruce RD, Walton M, et al. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;50:176-181.
86. Nachega J, Goliath R, Efron A, et al. Randomized trial of trained patient-nominated treatment supporters providing partial directly observed ART in South Aftican adults initiating HIV therapy. Presented at: 16th Conference on Retroviruses and Opportunistic Diseases; 2009; Montreal, Canada.
87. Sarna A, Luchters S, Geibel S, et al. Short-and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr. 2008;48:611-619.
88. Cochran W. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
89. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
90. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
91. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279:943-948.
92. Watkins K, Office HDR. Human Development Report 2007/2008: Fighting Climate Change: Human Solidarity in a Divided World.New York: United Nations Development Programme UN; 2007.
93. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
94. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed 1997;315: 629-634.
95. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676-680.
96. Team RDC. R: A language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007.
97. Franke M, Socci A, Kaigamba F, et al.Early self-reported adherence among patients receiving clinic-based and community-based care in rural Rwanda. Presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico; 2008.
98. Grodensky C, Golin C, Sunli A, et al. Effect on antiretroviral adherence of directly observed therapy (DOT) versus keep-on-my-person medication (KOM) among HIV-infected prisoners: The DOT-KOM Study. Presented at: 4th International Conference on HIV Treatment Adherence; 2009; Miami, FL.
99. Taiwo BO, Idoko JA, Otoh I, et al. Patient-selected treatment partner is associated with superior virologic response to first-line HAART in Jos, Nigeria. Presented at: 3rd International Conference on HIV Treatment Adherence; 2008; Jersey City, NJ. Abstract 167.
100. Munoz M, Finnegan K, Zeladita J, et al. Community-based DOT-HAART accompaniment in an urban resource-poor setting. AIDS Behav. 2009. [Epub ahead of print].
101. Lanzafame M, Trevenzoli M, Cattelan AM, et al. Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr. 2000;25:200-201.
102. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
103. Puigventos F, Riera M, Delibes C, et al. Adherence to antiretroviral drug therapy. A systematic review. Med Clin (Barc). 2002;119:130-137. [in Spanish].
104. Bradley-Ewing A, Thomson D, Pinkston M, et al. A qualitative examination of the indirect effects of modified directly observed therapy on health behaviors other than adherence. AIDS Patient Care STDS. 2008;22:663-668.
105. Mitty JA, Macalino G, Taylor L, et al. Directly observed therapy (DOT) for individuals with HIV: successes and challenges. MedGenMed. 2003;5:30.
106. Smith-Rohrberg D, Mezger J, Walton M, et al. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S48-S53.
107. Ford N, Nachega JB, Engel ME, et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374:2064-2071.
108. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2006;41:385-392.
109. Horberg M, Silverberg M, Hurley L, et al. Influence of prior antiretroviral experience on adherence and responses to new highly active anti-retroviral therapy regimens. AIDS Patient Care STDS. 2008;22:301-312.
110. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41:864-872.
111. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis. 2004;38(Suppl 5):S429-S436.
112. Smith-Rohrberg D, Altice FL. Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach. Clin Infect Dis. 2006; 43:1221-1222. Author reply 2-3.
113. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262-270.
114. Wood E, Kerr T, Tyndall MW, et al. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22: 1247-1256.
115. Flanigan TP, Taylor LE, Mitty JA. Use of community-based, directly observed therapy for HIV infection: lessons learned for treatment of hepatitis C virus infection. Clin Infect Dis. 2005;40(Suppl 5): S346-S348.
116. Behforouz HL, Kalmus A, Scherz CS, et al. Directly observed therapy for HIV antiretroviral therapy in an urban US setting. J Acquir Immune Defic Syndr. 2004;36:642-645.